Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Status:
Recruiting
Trial end date:
2027-03-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly
ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/
small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL),
mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia
(WM).